A lead COVID-19 vaccine candidate has been selected by Johnson & Johnson, after demonstrating promise in pre-clinical testing.
List view / Grid view
US Biomedical Advanced Research Development Authority (BARDA)
Filter the results
Grifols will leverage their resources to develop and test convalescent plasma-derived COVID-19 therapeutics in partnership with the FDA and BARDA.